Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Halozyme Therapeutics Inc. shares valued at $582,100 were sold by Torley Helen on Sep 24 ’24. At $58.21 per share, Torley Helen sold 10,000 shares. The insider’s holdings dropped to 676,744 shares worth approximately $39.36 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Torley Helen sold 10,000 shares, netting a total of over 563,370 in proceeds. Following the sale of shares at $56.34 each, the insider now holds 676,744 shares.
Before that, Torley Helen had sold 10,000 shares from its account. In a trade valued at $560,970, the PRESIDENT AND CEO traded Halozyme Therapeutics Inc. shares for $56.10 each. Upon closing the transaction, the insider’s holdings decreased to 10,000 shares, worth approximately $39.36 million.
As published in a research note from JP Morgan on September 19, 2024, Halozyme Therapeutics Inc. [HALO] has been rated down from an Overweight to a Neutral and the price target has been revised to $57 from $52. Analysts at Piper Sandler downgraded the stock from ‘”an Overweight”‘ to ‘”a Neutral”‘ outlook in a report released in early June. As of February 29, 2024, TD Cowen has initiated its “an Outperform” rating for HALO. Earlier on July 24, 2023, H.C. Wainwright initiated its rating. Their recommendation was “a Buy” for HALO stock.
Analyzing HALO Stock Performance
During the last five days, there has been a surge of approximately 4.10%. Over the course of the year, Halozyme Therapeutics Inc. shares have jumped approximately 57.36%. Shares of the company reached a 52-week high of $65.53 on 08/29/24 and a 52-week low of $33.15 on 02/05/24. A 50-day SMA is recorded $58.64, while a 200-day SMA reached $46.05. Nevertheless, trading volume fell to 1.34 million shares from 1.32 million shares the previous day.
Support And Resistance Levels for Halozyme Therapeutics Inc. (HALO)
According to the 24-hour chart, there is a support level at 56.78, which, if violated, would cause prices to drop to 55.40. In the upper region, resistance lies at 58.97. The next price resistance is at 59.77. RSI (Relative Strength Index) is 47.37 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -1.56, which suggests the price will decrease in the coming days. Percent R is at 66.17%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
